Article

HTA Quarterly Winter 2025 Summary

This edition features the conclusion of our three-part series on France’s Early Access Program (EAP), highlighting the potential of the National Health Database (SNDS) to streamline data collection and offering industry insights on enhancing the program. We also delve into the growing role of multilevel network meta-regression in health technology assessment (HTA), showcasing its ability to address challenges in comparing treatments with limited trial data. Lastly, we summarize findings from a study on leveraging Nordic real-world data to inform PICOs for Joint Clinical Assessments (JCAs), emphasizing the importance of proactive evidence generation and the unique value of Nordic health registries.
HTAQ Summer 2025

Article

The French National Health Database: An opportunity to produce real-world evidence for the Early Access Program?

HTAQ abstract

Article

Multilevel network meta-regression: A step forward in HTA evidence synthesis?

real world evidence

Article

Unlocking the potential of Nordic real-world data for PICO assessments in European HTA

Heard on the street

“In a world that feels fragmented, our work can help build bridges. Evidence can be a tool for dialogue and for designing policies that reflect both science and social values.”

– Dr. Andrés Pichon Riviere, Director General of the Institute of Clinical and Health Effectiveness (IECS) 

Source: HTAi 2025: the world conference on health technology assessment (IECS) kicked off in Buenos Aires

HTA by the numbers

9/25
The EMA had estimated that the Member State Coordination Group on Health Technology Assessment (HTACG) would need to conduct 17 JCAs for cancer medicines and 8 JCAs for Advance Therapy Medicinal Products (ATMPs) in 2025; 9 JCAs were underway as of September 2025.
Sources: New EU rules for health technology assessments become effective | European Medicines Agency (EMA) 
Updated - List of ongoing joint clinical assessments - Public Health

Connect with our team

Our team of leading value experts is dedicated to transforming evidence, policy insights, and market intelligence into effective global market access strategies. Let us help you navigate today’s complex healthcare landscape with confidence. Reach out to discover how we can support your goals.

Related resources

Article

Multilevel network meta-regression: A step forward in HTA evidence synthesis?
Learn more

Article

Unlocking the potential of Nordic real-world data for PICO assessments in European HTA
Learn more

Report

FDA programs on the horizon: What biopharma companies need to know
Learn more

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.